Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18365233 | 1.00 | SPR (0.40) | SPRATMLMNAMAPTHTT | |
| SCHEMBL15352349 | 0.83 | SLC6A3 (0.41) | ATMLMNAADRA2ACNR1TDP1 | |
| SCHEMBL18375984 | 0.83 | SLC6A3 (0.41) | ATMLMNAADRA2ACNR1TDP1 | |
| SCHEMBL12914999 | 0.76 | KMT2A (0.37) | SPRLMNAMAPTKMT2A | |
| SCHEMBL16675316 | 0.76 | KMT2A (0.37) | SPRLMNAMAPTKMT2A | |
| SCHEMBL12914976 | 0.75 | KMT2A (0.36) | SPRLMNAMAPTKMT2A | |
| SCHEMBL961100 | 0.73 | KMT2A (0.35) | SPRLMNAMAPTKMT2A | |
| SCHEMBL15362627 | 0.72 | ESR1 (0.40) | LMNAMAPTNPSR1CNR1TDP1 | |
| SCHEMBL16864100 | 0.72 | ESR1 (0.40) | LMNAMAPTNPSR1CNR1TDP1 | |
| SCHEMBL432793 | 0.65 | LMNA (0.45) | SPRLMNAMAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | SPR 1717/4885ATM 3766/4885LMNA 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.